Mounjaro
Dual-hormone therapy. Exceptional results.
Mounjaro (tirzepatide) is the breakthrough dual GIP/GLP-1 receptor agonist from Eli Lilly. FDA-approved for Type 2 diabetes and demonstrating extraordinary weight loss results in clinical trials — up to 22.5% body weight reduction — it represents a genuine step forward in metabolic medicine.
Key Benefits
- ✓Up to 22.5% average weight loss in SURMOUNT trials
- ✓Dual GIP/GLP-1 mechanism for superior efficacy
- ✓Significant improvement in blood sugar control
- ✓Reduces cardiovascular risk factors
- ✓Once-weekly injection
- ✓FDA-approved with growing long-term data
Quick Facts
Tirzepatide is the first medication to activate both the GIP and GLP-1 receptor simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that, when combined with GLP-1 agonism, produces a more powerful metabolic response than either target alone. The result is superior appetite suppression, better insulin secretion in response to meals, reduced glucagon release, and meaningful effects on adipose tissue metabolism. SURMOUNT trial data showed 22.5% average weight loss at the highest dose.
More from Weight Loss
You Might Also Like
All prescription treatments require approval from a licensed healthcare provider. Results may vary. This product has not been evaluated by the FDA for the specific indications described. Reclaimed is a telehealth platform — we facilitate connections between patients and licensed providers, not the practice of medicine directly. Please consult your provider with any questions about your treatment.